Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · SYRE · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
44
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Spyre Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
SYRE insider buying and selling by quarter
SYRE insider selling · SYRE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · SYRE ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
SYRE executive sell shares · SYRE board member insider trading · SYRE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 3, 2026 | Sloan Sheldon Chief Medical Officer | Option | 8,333 | $229K | Form 4 |
| Jun 3, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 8,333 | $625K | Form 4 |
| Jun 1, 2026 | Turtle Cameron CEO · Director | Sale | 3,557 | $247K | Form 4 |
| Jun 1, 2026 | Turtle Cameron CEO · Director | Sale | 8,149 | $575K | Form 4 |
| Jun 1, 2026 | Turtle Cameron CEO · Director | Sale | 3,294 | $235K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Option | 7,500 | $109K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Sale | 1,801 | $126K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Sale | 2,599 | $184K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Sale | 3,100 | $223K | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 2,404 | $174K | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 33,513 | $2.47M⚡ | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 24,814 | $1.86M⚡ | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 19,269 | $1.45M⚡ | Form 4 |
| May 1, 2026 | Burrows Scott L CFO | Option | 12,500 | $181K | Form 4 |
| May 1, 2026 | Burrows Scott L CFO | Sale | 12,500 | $892K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Option | 78,333 | $2.15M⚡ | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 21,306 | $1.48M⚡ | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 19,656 | $1.39M⚡ | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 8,777 | $628K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 12,777 | $932K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 10,358 | $764K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 5,059 | $377K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 400 | $30K | Form 4 |
| May 1, 2026 | Turtle Cameron CEO · Director | Sale | 5,300 | $369K | Form 4 |
| May 1, 2026 | Turtle Cameron CEO · Director | Sale | 3,600 | $255K | Form 4 |
Sloan Sheldon
Chief Medical Officer
Date
Jun 3
Shares
8,333
Price
$27.46
Value
$229K
Sloan Sheldon
Chief Medical Officer
Date
Jun 3
Shares
8,333
Price
$75.00
Value
$625K
HENDERSON MICHAEL THOMAS
Director
Date
May 8
Shares
33,513
Price
$73.72
Value
$2.47M ⚡
HENDERSON MICHAEL THOMAS
Director
Date
May 8
Shares
24,814
Price
$74.76
Value
$1.86M ⚡
HENDERSON MICHAEL THOMAS
Director
Date
May 8
Shares
19,269
Price
$75.35
Value
$1.45M ⚡
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
78,333
Price
$27.46
Value
$2.15M ⚡
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
21,306
Price
$69.53
Value
$1.48M ⚡
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
19,656
Price
$70.61
Value
$1.39M ⚡
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
8,777
Price
$71.56
Value
$628K
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
12,777
Price
$72.94
Value
$932K
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
10,358
Price
$73.74
Value
$764K
Sloan Sheldon
Chief Medical Officer
Date
May 1
Shares
5,059
Price
$74.60
Value
$377K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About SYRE insider trading
SYRE insider trades
Spyre Therapeutics, Inc. (SYRE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Turtle Cameron (CEO · Director), Burrows Scott L (CFO), Sloan Sheldon (Chief Medical Officer). Over the past 12 months, 4 insiders have filed transactions with the SEC. SYRE insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Spyre Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
SYRE insider trading · 5 questionsThe insiders of Spyre Therapeutics, Inc. (SYRE) include executives and directors such as Turtle Cameron (CEO · Director), Burrows Scott L (CFO), Sloan Sheldon (Chief Medical Officer), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026